This paper provides a valuable observation that imiquimod, a compound often used to induce a psoriasis-like skin inflammation in mice, has a TLR7-independent effect acting through the unfolded protein ...

Johnson & Johnson said the FDA has approved its once-daily psoriasis pill Icotyde. Icotyde targets IL-23, rivaling best-selling shots Tremfya and Skyrizi. J&J hasn't announced how much Icotyde will ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipated daily ...

For many people living with psoriasis, the red, scaly skin patches are only part of the story. Another challenge is the uncertainty about whether there is anything they can do themselves to help ...

Please provide your email address to receive an email when new articles are posted on . New position statement features two definitions of psoriasis severity: mild and moderate to severe. The change ...

Psoriasis, a chronic autoimmune condition, causes inflammation in the skin, most often leading to thick, scaly areas called plaques. An overactive immune system speeds up skin cell development, ...

Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition and ...

A research team led by Erwin F. Wagner from the Medical University of Vienna has discovered a previously unknown molecular mechanism that contributes to the development of psoriasis—and at the same ...

A research team led by Erwin F. Wagner from the Medical University of Vienna has discovered a previously unknown molecular mechanism that contributes to the development of psoriasis - and at the same ...

NEW YORK CITY — Dermatologists should be thinking about offering hormonally-active weight loss drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as part of routine care for psoriasis ...

GLP-1 agonists appeared to have a bigger impact on the physical and mental health of patients with psoriasis compared with other patients, a large retrospective cohort study showed. Reductions in ...

Sept 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's (BMY.N), opens new ...